Currently, in clinical trials, the first saRNA treatment (MTL-CEBPA) targets and up-regulates the myeloid transcription factor CCAAT enhancer binding protein (CEBPA) in advanced hepatocellular cancer [17, 18]. This evidence concerns the gene CEBPA and hepatocellular carcinoma.